Print

NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region  
7/22/2009 8:58:11 AM

DUBAI, United Arab Emirates and SAN FRANCISCO, July 22 /PRNewswire/ -- NewBridge Pharmaceuticals, a specialty pharmaceutical, biologics, and medical device company serving the Middle East, Africa, Turkey & Caspian regions, today announced that it has entered into an exclusive license and supply agreement with Axcan Pharma for Pylera®, an innovative 3-in-1 capsule therapy for the eradication of Helicobacter pylori, a bacterium now recognized as being the main cause of gastric and duodenal ulcers. Pursuant to the agreement, NewBridge is entitled to obtain exclusive rights in certain markets where it obtains required regulatory approvals and launches the product. The product should be launched in Q4 2010.
//-->